EUCTR2021-005725-24-DE进行中（未招募）1 期
Phase 1b/2, Open-Label Study to Evaluate Safety and Tolerability of Epcoritamab in Combination with Anti-Neoplastic Agents in Subjects with Non-Hodgkin Lymphoma - Non-Hodgkin Lymphoma: Epcoritamab in Combination with Anti-Neoplastic Agents
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 394
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Adult male or female, at least 18 years old
- •2. (Arms 1, 2, 3 and 4) Diagnosis of diffuse large B-cell lymphoma (DLBCL) (de novo or histologically transformed from follicular lymphoma or nodal marginal zone lymphoma) with histologically confirmed CD20+ disease, inclusive of the following according to World Health Organization (WHO) 2016 classification and documented in pathology report:
- •High-grade B cell lymphoma with MYC and BCL-2 and/or BCL-6 translocations per WHO 2016 (double-hit” or triple-hit”)
- •Note: High-grade B-cell lymphomas NOS or other double-/triple-hit lymphomas (with histologies not consistent with DLBCL) are not eligible
- •Follicular lymphoma Grade 3B
- •3. Subject must have Eastern Cooperative Oncology Group (ECOG) performance status 0 – 2
- •4. Subject must have 1 or more measurable disease sites:
- •A PET/CT scan demonstrating PET-positive lesion(s)
- •At least 1 measurable nodal lesion (long axis = 1.5cm and short axis > 1.0 cm) or = 1 measurable extra-nodal lesion (long axis = 1.0 cm) on CT scan or MRI
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 374
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 20
排除标准
- •1.Diagnosis of High-grade B-cell lymphomas NOS or other double-/triple-hit lymphomas (with histologies not consistent with DLBCL)
- •2. Subjects who have had prior treatment with epcoritamab or any other bispecific antibody targeting CD3 and CD20
研究者
相似试验
进行中（未招募）
1 期
This study is to evaluate the safety and tolerability of Epcoritamab in Combination with Anti-Neoplastic Agents in Subjects with Non-Hodgkin LymphomaEUCTR2021-005725-24-DKAbbVie Deutschland GmbH & Co. KG394
进行中（未招募）
1 期
This study is to evaluate the safety and tolerability of Epcoritamab in Combination with Anti-Neoplastic Agents in Subjects with Non-Hodgkin LymphomaB-cell Non-Hodgkin's lymphoma, diffuse large B-cell lymphomaMedDRA version: 21.0Level: PTClassification code 10003903Term: B-cell lymphoma refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10012822Term: Diffuse large B-cell lymphoma refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: HLGTClassification code 10025320Term: Lymphomas non-Hodgkin's B-cellSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2021-005725-24-ESAbbVie Deutschland GmbH & Co. KG132
进行中（未招募）
1 期
This study is to evaluate the safety and tolerability of Epcoritamab in Combination with Anti-Neoplastic Agents in Subjects with Non-Hodgkin LymphomaEUCTR2021-005725-24-NLAbbVie Deutschland GmbH & Co. KG394
招募中
1 期
This study is to evaluate the safety and tolerability of Epcoritamab in Combination with Anti-Neoplastic Agents in Subjects with Non-Hodgkin LymphomaB-cell Non-Hodgkin's lymphoma, diffuse large B-cell lymphomaMedDRA version: 20.0Level: HLGTClassification code: 10025320Term: Lymphomas non-Hodgkin's B-cell Class: 10029104MedDRA version: 21.0Level: PTClassification code: 10003903Term: B-cell lymphoma refractory Class: 100000004864MedDRA version: 21.0Level: PTClassification code: 10012822Term: Diffuse large B-cell lymphoma refractory Class: 100000004864CTIS2023-505347-38-00AbbVie Deutschland GmbH & Co. KG87
招募中
2 期
Phase 1b/2, Open Label Study to Evaluate Safety and Tolerability of Epcoritamab in Combination with Anti-Neoplastic Agents in Subjects with Non-Hodgkin LymphomaNL-OMON53475AbbVie B.V.10